Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04608318
Title Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) (CLL17)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors German CLL Study Group
Indications

chronic lymphocytic leukemia

Therapies

Ibrutinib

Ibrutinib + Venetoclax

Obinutuzumab + Venetoclax

Age Groups: adult | senior
Covered Countries ITA | ESP | DEU | BEL | AUT


No variant requirements are available.